Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

Update for June 28, 2022

6/27/2022

 
Regulatory Update

Menarini and Radius submitted an NDA elacestrant for the treatment of ER+/HER2- advanced or metastatic breast cancer.

The EMA’s CHMP recommended approval of lenacapavir and valoctocogene roxaparvovec.

Announced Research Updates

Roche announced that in a 260 to 416 week, 252 patient, Phase II trial, treatment with crenezumab did not slow the decline in cognition in cognitively unimpaired individuals who have no clinical symptoms of Alzheimer’s disease and carry the PSEN1 E280A autosomal dominant mutation.

Ionis and AstraZeneca announced interim results at 35 weeks from the 66-week, 168 patient open-label, Phase III NEURO-TTRansform trial, where treatment with eplontersen reduced serum transthyretin (TTR) concentration and improved the modified Neuropathy Impairment Score +7 (mNIS+7) compared to a historical cohort of placebo patients from the inotersen NEURO-TTR trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

PTC Therapeutics announced that in a 48-week, 359 patient, Phase III trial, treatment with ataluren the the decline in six-minute walking distance compared to placebo (53 m vs 67.4 m) in patients with Duchenne muscular dystrophy.

Galderma announced that in the 16-week, 274 patient, Phase III, OLYMPIA 2 trial, 38% of patients treated with nemolizumab achieved clearance or almost-clearance of skin lesions, when assessed using the investigator’s global assessment (IGA) score, compared to 11% with placebo in patients with moderate to severe prurigo nodularis. 56% of nemolizumab patients achieved at least a four-point reduction in itch, as measured by the peak-pruritus numerical rating scale (PP-NRS) score, compared to 21% with placebo.

Italfarmaco announced that in the 18-month, 179 patient, Phase III, EPIDYS trial, adding givinostat to corticosteroids resulted in a reduction in the decline of time required to climb four stairs compared to corticosteroids only in ambulatory DMD patients.

Gilead announced that in the 48-week, 150 patient, Phase III, MYR301 trial, undetectable levels of HDV RNA or a 2 log(10) IU/mL decrease and normalization of ALT levels was achieved in 45% of patients treated with bulevirtide 2 mg and 48% with 10 mg compared to 2% with placebo of untreated chronic HDV patients.

Published Research Updates

In the 454 patient, Phase III, PANTHER trial, adding pevonedistat to azactidine did not improve event-free survival compared to azactidine alone in patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia or low-blast acute myeloid leukemia.

In a 12-day, 62 patient, Phase IIa trial, vaccination with RSVpreF demonstrated 86.7% efficacy in preventing respiratory syncytial virus (RSV) compared to placebo in a challenge study of healthy adults 18 to 50. 

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.